IDO1 and rheumatoid arthritis: Sulfasalazine, an anti-inflammatory and immunosuppressive drug commonly used in rheumatoid arthritis and ulcerative colitis treatment [209,210], effectively inhibits LPS-dependent nuclear factor-kB activation and release of pro-inflammatory cytokines in the placenta, leading to decreased IDO expression [211].